Medtronic wins FDA nod for connected, predictive CGM system

This article was originally published here

Medtronic (NYSE:MDT) said today that its Guardian Connect continuous glucose monitoring system won FDA approval for people with diabetes ages 14 to 75.

The medtech titan touted its system as the first connected standalone CGM designed to help people with diabetes avoid high and low glucose events.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic wins FDA nod for connected, predictive CGM system appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply